(Q33853468)

29 July 2017

1 reference

title

Antimalarials: unapproved uses or indications (English)

1 reference

29 July 2017

0 references

Wolf R

1

1 reference

29 July 2017

Wolf D

series ordinal

2

1 reference

29 July 2017

Ruocco V

series ordinal

3

1 reference

29 July 2017

publication date

1 January 2000

1 reference

29 July 2017

published in

Clinics in Dermatology

1 reference

29 July 2017

volume

18

1 reference

29 July 2017

issue

1

1 reference

29 July 2017

page(s)

17-35

1 reference

Anti-malarials in dermatology

29 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

Treatment of lupus erythematosus with mepacrine

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

Bioavailability of hydroxychloroquine tablets in healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

Occasional series: lupus around the world systemic lupus erythematosus research in the Asia-Pacific region: a co-ordinated and co-operative approach

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

Clinical pharmacokinetics of antimalarial drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

Metabolism of chloroquine and hydroxychloroquine in albino and pigmented rats

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

STUDIES ON THE CHEMOTHERAPY OF THE HUMAN MALARIAS. VI. THE PHYSIOLOGICAL DISPOSITION, ANTIMALARIAL ACTIVITY, AND TOXICITY OF SEVERAL DERIVATIVES OF 4-AMINOQUINOLINE.

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

Tissue distribution of chloroquine, hydroxychloroquine, and desethylchloroquine in the rat

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

1 reference

7 January 2021

Studies on the mechanism of drug-binding to melanin

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

Distribution of an 125I-labelled chloroquine analogue in a pregnant macaca monkey

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

Absorption of antimalarial drugs in human skin; spectroscopic and chemical analysis in epidermis and corium

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

Responses of the secretory coil of the human eccrine sweat gland to controlled injury

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

1 reference

7 January 2021

The distribution of chloroquine in man after fatal poisoning

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

Acrodermatitis chronica atrophicans; report of a case treated with chloroquine phosphate (aralen).

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

Treatment of Lyme arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

Treatment of Chronic Lyme Arthritis with Hydroxychloroquine

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

Success and failure in the treatment of acrodermatitis chronica atrophicans

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

Actinic reticuloid. Response to combination treatment with azathioprine, hydroxychloroquine, and prednisone

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

Chronic actinic dermatitis. An analysis of 51 patients evaluated in the United States and Japan

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

Chronic actinic dermatitis: results of patch and photopatch tests with Compositae, fragrances, and pesticides.

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

Antimalarials for children

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

Postmenopausal frontal fibrosing alopecia: a frontal variant of lichen planopilaris

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

Pseudopelade of Brocq

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

Hydroxychloroquine improves airflow and lowers circulating IgE levels in subjects with moderate symptomatic asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

Alternative pharmacotherapies for steroid-dependent asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

Hydroxychloroquine is useful in the management of atopic dermatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

Chronic ulcerative stomatitis associated with a specific immunologic marker

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

Patients with erosive lichen planus may have antibodies directed to a nuclear antigen of epithelial cells: a study on the antigen nature

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

Ten cases of chronic ulcerative stomatitis with stratified epithelium-specific antinuclear antibody

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

Chronic ulcerative stomatitis associated with stratified epithelial specific antinuclear antibodies. A case report of a newly described disease entity

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

Chronic ulcerative stomatitis with stratified epithelium-specific antinuclear antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

Chronic ulcerative stomatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

1 reference

7 January 2021

Cutaneous lesions of dermatomyositis are improved by hydroxychloroquine

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

Dermatomyositis without muscle weakness. Long-term follow-up of 12 patients without systemic corticosteroids

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

Eosinophilic fasciitis: clinical spectrum and therapeutic response in 52 cases

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

Eosinophilic fasciitis in an African--possible benefit of chloroquine treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

Epidermolysis bullosa hereditaria treated with antimalarials

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

Hydroxychloroquine in the treatment of chronic erythema nodosum

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

Hydroxychloroquine and chronic erythema nodosum

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

Immune suppression by lysosomotropic amines and cyclosporine on T-cell responses to minor and major histocompatibility antigens: does synergy exist?

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

The lysosomotropic amines, chloroquine and hydroxychloroquine: a potentially novel therapy for graft-versus-host disease

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

Generalized granuloma annulare: clinical and laboratory findings in 100 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

Disseminated granuloma annulare; report of a case treated with chloroquine phosphate (aralen).

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

A case of generalized granuloma annulare responding to hydroxychloroquine

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

Antimalarials for control of disseminated granuloma annulare in children

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

Lichen planus of the nail: treatment with antimalarials

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

Hydroxychloroquine sulfate (Plaquenil) improves oral lichen planus: An open trial

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

Isolated lichen planus of the lip successfully treated with chloroquine phosphate

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

A prospective follow-up study of 570 patients with oral lichen planus: persistence, remission, and malignant association

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

A prospective study of findings and management in 214 patients with oral lichen planus

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

The therapy of oral lichen planus

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

Oral lichen planus: topical and systemic therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

Treatment of lichen planus. An evidence-based medicine analysis of efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

Lichen planus actinicus (lichen planus in subtropical countries).

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

Summertime actinic lichenoid eruption (lichen planus actinicus)

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

Induction of actinic lichen planus with artificial UV sources

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

Lichen planus actinicus

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

Lichen planus subtropicus: direct immunofluorescence findings and therapeutic response to hydroxychloroquine

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

Actinic lichen planus: treatment with antimalarials

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

Corticosteroid-sparing effect of hydroxychloroquine in a patient with early-onset Weber-Christian syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

Cyclophosphamide-induced remission in Weber-Christian panniculitis

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

Chloroquine-induced remission of nodular panniculitis present for 15 years

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

ANCA-positive lupus erythematodes profundus. Successful therapy with low dosage dapsone

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

Connective tissue panniculitis

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

Immunologic concepts of light reactions in lupus erythematosus and polymorphous light eruptions. I. The mechanism of action of hydroxychloroquine

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

POLYMORPHOUS LIGHT ERUPTION. A TEN-YEAR FOLLOW-UP AND EVALUATION.

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

The effect of beta-carotene in combination with canthaxanthin, Ro 8-8427 (Phenoro), in treatment of polymorphous light eruptions

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

The treatment of polymorphic light eruptions with chloroquine

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

Quinacrine (atabrine) in treatment of solar dermatoses

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

Controlled therapeutic trials in polymorphic light eruption

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

Hydroxychloroquine in polymorphic light eruption: a controlled trial with drug and visual sensitivity monitoring

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

Lichen sclerosus at atrophicus

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

Extensive lichen sclerosus et atrophicus with bullae and ulceration--improvement with hydroxychloroquine

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

Extensive bullous lichen sclerosus et atrophicus unresponsive to hydroxychloroquine

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

EFFECTS OF CHLOROQUINE ON PATIENTS WITH CUTANEOUS PORPHYRIA OF THE "SYMPTOMATIC" TYPE.

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

Porphyria during chloroquine therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

Effect of chloroquine on hepatic uroporphyrin metabolism in patients with porphyria cutanea tarda.

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

The Molecular Basis of the Action of Chloroquine in Porphyria Cutanea Tarda

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

The therapeutic effect of chloroquine. Hepatic recovery in porphyria cutanea tarda

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

Biochemical effects of chloroquine therapy in porphyria cutanea tarda

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

Hydroxychloroquine treatment of porphyria cutanea tarda

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

Low-dose oral chloroquine in the treatment of porphyria cutanea tarda

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

Two cases of infantile porphyria cutanea tarda: successful treatment with oral S-adenosyl-L-methionine and low-dose oral chloroquine

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

Childhood-onset porphyria cutanea tarda: successful therapy with low-dose hydroxychloroquine (Plaquenil).

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

Treatment of porphyria cutanea tarda with chloroquine and phlebotomy

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

The treatment of sarcoidosis with chloroquine

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

Sarcoidosis treated with chloroquine

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

Ghloroquine Therapy in 43 Patients with Intrathoracic and Cutaneous Sarcoidosis

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

Chloroquine in pulmonary sarcoidosis

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

Cutaneous ulcers in sarcoidosis

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

Longitudinal study of chronic sarcoidosis with low-dose maintenance corticosteroid therapy. Outcome and complications

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

THE RESPONSE OF HYPERCALCEMIA IN SARCOIDOSIS TO CHLOROQUINE.

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

The effects of chloroquine on serum 1,25-dihydroxyvitamin D and calcium metabolism in sarcoidosis

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

Intralesional chloroquine for the treatment of cutaneous sarcoidosis

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

Treatment of primary Sjögren's syndrome with hydroxychloroquine

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

Hydroxychloroquine treatment for primary Sjögren's syndrome: a two year double blind crossover trial

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

Respiratory function in systemic lupus erythematosus: relation with activity and severity.

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

1 reference

7 January 2021

Solar- vs heat-induced urticaria

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

1 reference

7 January 2021

Treatment of pustular psoriasis and pustular bacterid with quinacrine (atabrine)

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

Action of synthetic antimalarial drugs on psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

Is transglutaminase the mediator between antimalarial drugs and psoriasis?

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

Psoriatic arthritis: A clinical, immunologic and HLA study of 100 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

The in vitro effect of hydroxychloroquine on skin morphology and transglutaminase

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

Fluorescence probe measurement of the intralysosomal pH in living cells and the perturbation of pH by various agents

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

Effect of weak bases on the intralysosomal pH in mouse peritoneal macrophages

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

Cytoplasmic vacuolation of mouse peritoneal macrophages and the uptake into lysosomes of weakly basic substances

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

Acid-vesicle function, intracellular pathogens, and the action of chloroquine against Plasmodium falciparum

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

The dominant self and the cryptic self: shaping the autoreactive T-cell repertoire

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

Chloroquine affects biosynthesis of Ia molecules by inhibiting dissociation of invariant (gamma) chains from alpha-beta dimers in B cells

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

Signals and signs for lymphocyte responses

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

Immunosuppressive potential of antimalarials

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

Chloroquine inhibits tumor necrosis factor production by human macrophages in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

Chloroquine inhibits T cell proliferation by interfering with IL-2 production and responsiveness

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

Effects of chloroquine, mefloquine and quinine on natural killer cell activity in vitro. An analysis of the inhibitory mechanism

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

Effect of chloroquine on human lymphocyte proliferation

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

Effects of drugs onin vitro mitogenic stimulation of peripheral mononuclear cells

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

SUPPRESSION OF IN VITRO LYMPHOCYTE RESPONSES BY CHLOROQUINE.

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

Effects of some antimalarial drugs on rat inflammatory polymorphonuclear leukocyte function

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

Effects of amodiaquine, chloroquine, and mefloquine on human polymorphonuclear neutrophil function in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

Potential usefulness of protease inhibitor and chloroquine in the treatment of transfusion-associated graft-versus-host disease

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

Apoptosis and autoimmune disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

Induction of apoptosis in peripheral blood lymphocytes following treatment in vitro with hydroxychloroquine

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

Antibodies to denatured deoxyribonucleic acid in lupus erythematosus serum. V. Mechanism of DNA-anti-DNA inhibition by chloroquine

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

Effect of quinacrine (atabrine) upon lupus erythematosus phenomenon

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

Affinity between the lupus erythematosus serum factor and cell nuclei and nucleoprotein

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

Quinacrine antagonizes the effects of Na,K-ATPase inhibitors on renal prostaglandin E2 release but not their effects on renin secretion

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

Chloroquine inhibits stimulated platelets at the arachidonic acid pathway

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

Mechanism of cationic amphiphilic drug inhibition of purified lysosomal phospholipase A1.

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

Potential therapeutic efficacy of inhibitors of human phospholipase A2 in septic shock

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

Influence of cationic amphiphilic drugs on the phosphatidylcholine hydrolysis by phospholipase A2.

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

Amiodarone--an inhibitor of phospholipase activity: a comparative study of the inhibitory effects of amiodarone, chloroquine and chlorpromazine

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

Chloroquine inhibition of cholera toxin

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

Antimalarial drugs inhibit phospholipase A2 activation and induction of interleukin 1beta and tumor necrosis factor alpha in macrophages: implications for their mode of action in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

Mepacrine inhibition of bradykinin-induced contractions of the rabbit ear vein

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

Effect of chloroquine on isolated mast cells

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

The effects of non-steroidal inhibitors of phospholipase A2 on leukotriene and histamine release from human and guinea-pig lung.

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

Enhancement of the antimalarial effect of chloroquine by chloropheniramine in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

Histamine N-methyl transferase: inhibition by drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

Stereoselective inhibition by chloroquine of histamine N-methyltransferase in the human liver and brain

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

Nitric oxide as a secretory product of mammalian cells

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

Vascular endothelial cells synthesize nitric oxide from L-arginine

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

A novel citrulline-forming enzyme implicated in the formation of nitric oxide by vascular endothelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

Chloroquine stimulates nitric oxide synthesis in murine, porcine, and human endothelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

Transferrin: a potential source of iron for oxygen free radical-mediated endothelial cell injury.

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

Action of chloroquine on nitric oxide production and parasite killing by macrophages

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

Chloroquine: mode of action

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

Antimalarials: Effects on in vivo and in vitro Protein Synthesis

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

Synthetic models of deoxyribonucleic acid complexes with antimalarial compounds. I. Interaction of aminoquinoline with adenine and thymine

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

Synthetic models of deoxyribonucleic acid complexes with antimalarial compounds. 3. Forces involved in the stacking interaction between aminoquinoline and the nucleotide bases

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

Synthetic models of deoxyribonucleic acid complexes with antimalarial compounds. Comparative ultraviolet and proton magnetic resonance study of quinoline-base, quinoline-quinoline, and base-base stacking interactions

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

Synthetic models of DNA complexes with antimalarial compounds. 2. The problem of guanine specificity in chloroquine binding

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

Sequence preference of chloroquine binding to DNA and prevention of Z-DNA formation

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

Fluorescence-determined preferential binding of quinacrine to DNA

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

DNA: Reaction with Chloroquine

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

Reactions of quinine, chloroquine, and quinacrine with DNA and their effects on the DNA and RNA polymerase reactions

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

Inhibition of murine RNA tumor virus replication and oncogenesis by chloroquine

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

Selective growth inhibition of ductal pancreatic adenocarcinoma cells by the lysosomotropic agent chloroquine

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

Chloroquine as a hyperthermia potentiator.

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

Chloroquine enhancement of anticancer drug cytotoxicity in multiple drug resistant human leukemic cells

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

Drug-mediated antigenic changes in murine leukemia cells: antagonistic effects of quinacrine, an antimutagenic compound

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

Anticarcinogenic activity of quinacrine in the rat mammary gland.

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

The antimutagenic action of polyamines: suppression of the mutagenic action of an E. coli mutator gene and of 2-aminopurine

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

Antimelanoma activity of chloroquine, an antimalarial agent with high affinity for melanin

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

Effect of chloroquine on erythematous and carcinogenic response to ultraviolet light. Demonstrated in experimental animals

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

The primary histologic lesion of seborrheic dermatitis and psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

The "Spectral Shift" Phenomenon of Chloroquine

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

Sensitivity to UV light during treatment with chloroquine in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

4-Aminoquinoline antimalarials enhance UV-B induced c-jun transcriptional activation

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

Mechanism of action of hydroxychloroquine as an antirheumatic drug

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900092-9

7 January 2021

10.1016/S0738-081X(99)00092-9

Identifiers

DOI

1 reference

29 July 2017

1 reference